Vibliome
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Vibliome Therapeutics is a private, Bozeman, Montana-based biotechnology company founded in 2017 and led by CEO Robert Goodwin. It discovered a novel systematic approach to developing small-molecule kinase inhibitors with unique selectivity profiles — drugs that target the 500+ kinases in the human genome controlling nearly all cellular functions. The company's chemistry platform supports many variations while keeping a common general architecture, with applications in oncology and precision medicine. It has raised about $38.1 million from investors including Deerfield Management and the Male Contraception Initiative, and holds 19 patents.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Vibliome Therapeutics was founded in Bozeman, Montana in 2017, developing its kinase-inhibitor chemistry platform.
- Fundraising
The company raised about $38.1 million across funding rounds, with Deerfield Management and the Male Contraception Initiative as investors; its latest reported round was Series A-II.
- Operating
Vibliome remains a private drug-discovery company with 11 employees and 19 patent documents; no published evidence of a shutdown or acquisition was found.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.